Overview

Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
NGM Biopharmaceuticals, Inc
Treatments:
Pembrolizumab